Renub

    Press Release:

    United States Vaccine Market is forecasted to be more than US$ 11.4 Billion by the end of year 2026

    United States Vaccine Market By Type (Influenza, Retrovirus, Hepatitis, Polio, DTap, HIB, Pneumococcal Conjugate, Varicella, MMR and HPV), Products and Pipeline, Companies

    Excel: 4 Hours
    PDF: 4 Hours
    Jan 2020
    Pages: 241

    Get Free Customization in this Report

    The average human life span has grown significantly primarily due to vaccination. Vaccines have transformed public health throughout the world, especially for children. In the United States, among the various diseases like Influenza, Rotavirus, Hepatitis (Hepatitis A and Hepatitis B), Polio, DTap, HIB, Pneumococcal conjugate, Varicella, MMR and HPV, influenza is the most common viral infection. Quadrivalent is the most common flu vaccines in the United States, which was licensed in the year 2012. According to Renub Research, United States Vaccine Market is poised to reach US$ 11.4 Billion by 2026.

     


    Although influenza can catch anyone anytime in the year, usually it spreads between May to October. So in August National Immunization Awareness day is being celebrated to increase the awareness and the importance of vaccination in the nation. These immunizations awareness and government initiatives have helped to prevent 2-3 million deaths annually according to the World Health Organisation. There is no other health intervention as simple, powerful, and cost-effective as a ‘vaccine’.


    In this report, we have studied key players like GlaxoSmithKline, plc, Merck & Co, Sanofi Pasteur and Pfizer, Inc their trends and implication which has given these companies to view in a strategic way. Apart from that, companies are evaluated on parameters like

    •    Overviews
    •    Recent Developments
    •    Revenues
    •    Vaccinations Pipeline & Clinical Trials


    Renub Research report titled “United States Vaccine Market By Vaccine Type (Vaccines Market, Immunized Population and Administered Doses), Influenza (Trivalent Flu Vaccine and Quadrivalent Flu Vaccine), Retrovirus, Hepatitis (Hepatitis A and B), Polio, DTap, HIB, Pneumococcal Conjugate, Varicella, MMR and HPV) Vaccines Products and Pipeline, Company Analysis (GlaxoSmithKline, plc, Merck & Co, Sanofi Pasteur and Pfizer, Inc.)” provides an all-encompassing analysis on the United States Vaccine Industry.


    All the 10 Vaccines have been studied from 3 points

    •    Vaccines Market
    •    Immunized Population (Infants)
    •    Doses of Vaccines Administered

     


    Vaccine Type - The Report Covers the Market, Immunized Population and Administered Doses of all the 10 diseases

    1.    Influenza Vaccines
    2.    Retrovirus
    3.    Hepatitis A & B
    4.    Polio
    5.    DTaP
    6.    HIB
    7.    Pneumococcal conjugate
    8.    Varicella
    9.    MMR
    10.    HPV


    All the company analysis has been covered from 4 Viewpoints

    •    Overview
    •    Recent Developments
    •    Revenue Analysis
    •    Vaccinations Pipeline & Clinical Trials

     


    Company Analysis

    •    GlaxoSmithKline, plc
    •    Merck & Co
    •    Sanofi Pasteur
    •    Pfizer, Inc.

     

    If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team at info@renub.com

    1.    Introduction

    2.    Research & Methodology
    3.    Executive Summary

    4.    Market Dynamics

    4.1    Growth Drivers
    4.2    Challenges


    5.    United States Vaccine Analysis

    5.1    Vaccine Market
    5.2    Immunized Population
    5.3    Doses of Vaccines Administered


    6.    Share Analysis

    6.1    Market Share by Vaccine Type
    6.2    Volume Share by Vaccine Type


    7.    Disease wise – Vaccines Market& Volume and Forecast

    7.1    Influenza Vaccines Market & Types

    7.1.1    Trivalent Flu Vaccine
    7.1.2    Quadrivalent Flu Vaccine
    7.1.3    Administered Doses

    7.2    Rotavirus

    7.2.1    Vaccines Market
    7.2.2    Immunized Population (Infants)
    7.2.3    Administered Doses

    7.3    Hepatitis B

    7.3.1    Vaccines Market
    7.3.2    Immunized Population (Infants)
    7.3.3    Administered Doses
    7.3.4    Hepatitis A

    7.4    Polio

    7.4.1    Vaccines Market
    7.4.2    Immunized Population (Infants + Children)
    7.4.3    Administered Doses

    7.5    DTaP

    7.5.1    Vaccines Market
    7.5.2    Immunized Population
    7.5.3    Administered Doses

    7.6    HIB

    7.6.1    Vaccines Market
    7.6.2    Immunized Population (Infants)
    7.6.3    Administered Doses

    7.7    Pneumococcal conjugate

    7.7.1    Vaccines Market
    7.7.2    Immunized Population (Infants)
    7.7.3    Administered Doses

    7.8    Varicella

    7.8.1    Vaccines Market
    7.8.2    Immunized Population (Infants + 4-6 years old)
    7.8.3    Administered Doses

    7.9    MMR

    7.9.1    Vaccines Market
    7.9.2    Immunized Population (Infants + 4-6 years old)
    7.9.3    Administered Doses

    7.10    HPV

    7.10.1    Vaccines Market
    7.10.2    Immunized Population (Immunized Girl)
    7.10.3    Administered Doses


    8.    Vaccines – Products and Pipeline

    8.1    GlaxoSmithKline, plc
    8.2    Merck & Co
    8.3    Sanofi Pasteur
    8.4    Pfizer, Inc.


    9.    Top Mergers and Acquisitions in the Vaccine Industry

    10.    Key Players

    10.1    GlaxoSmithKline, plc.’s Vaccines Sales
    10.2    Merck & Co. Vaccines Sales
    10.3    Sanofi Pasteur’s Vaccines Sales
    10.4    Pfizer, Inc.’s Vaccines Sales

     

     

    List of Figures:

    Figure-01:        United States – Vaccine Market (Million US$), 2016 – 2019
    Figure-02:        United States – Forecast For Vaccine Market (Million US$), 2020 – 2026
    Figure-03:        United States – Immunized Population (Million), 2016 – 2019
    Figure-04:        United States – Vaccine Market (Million US$), 2016 – 2019
    Figure-05:        United States – Forecast For Vaccine Market (Million US$), 2020 – 2026
    Figure-06:        United States – Immunized Population (Million), 2016 – 2019
    Figure-07:        United States – Forecast for Immunized Population (Million) - 2020-2026 
    Figure-08:        United States – Doses of Vaccines Administered (Million), 2016 – 2019
    Figure-09:        United States – Forecast For Doses of Vaccines Administered (Million), 2020 – 2026
    Figure-10:        United States – Influenza Vaccines Market (Million US$), 2015 – 2019
    Figure-11:        United States – Forecast For Influenza Vaccines Market (Million US$), 2020 – 2026
    Figure-12:        United States – Trivalent flu Vaccines (Million US$), 2014 – 2019
    Figure-13:        United States – Forecast For Trivalent flu Vaccine (Million US$), 2020 – 2026
    Figure-14:        United States – Quadrivalent flu Vaccine (Million US$), 2017– 2019 
    Figure-15:        United States – Forecast For Quadrivalent flu Vaccine (Million US$), 2020 – 2026
    Figure-16:        United States – Administered Doses (Million), 2017 – 2019
    Figure-17:        United States – Forecast For Administered Doses (Million), 2020 – 2026
    Figure-18:        United States – Rotavirus Vaccines Market (Million US$), 2015 – 2019
    Figure-19:        United States – Forecast For Rotavirus Vaccines Market (Million Pound), 2020 – 2026
    Figure-20:        United States – Rotavirus Immunized Infants (Million), 2015 – 2019
    Figure-21:        United States – Forecast For Rotavirus Immunized Infants (Million), 2020 – 2026
    Figure-22:        United States – Rotavirus Administered Doses (Million), 2015 – 2019
    Figure-23:        United States – Forecast For Rotavirus Administered Doses (Million), 2020 – 2026
    Figure-24:        United States – Hepatitis B Vaccines Market (Million US$), 2015 – 2019
    Figure-25:        United States – Forecast For Hepatitis B Vaccines Market (Million US$), 2020 – 2026
    Figure-26:        United States – Hepatitis B Immunized Population (Million), 2015 – 2019
    Figure-27:        United States – Forecast For Hepatitis B Immunized Population (Million), 2020 – 2026
    Figure-28:        United States – Hepatitis B Administered Doses (Million), 2015 – 2019
    Figure-29:        United States – Forecast For Hepatitis B Administered Doses (Million), 2020 – 2026
    Figure-30:        United States – Hepatitis A Vaccines Market (Million US$), 2015 – 2019
    Figure-31:        United States – Forecast For Hepatitis A Vaccines Market (Million US$), 2020 – 2026
    Figure-32:        United States – Hepatitis A Immunized Infants (Million), 2015 – 2019
    Figure-33:        United States – Forecast For Hepatitis A Immunized Infants (Million), 2020 – 2026
    Figure-34:        United States – Hepatitis B Administered Doses (Million), 2015 – 2019
    Figure-35:        United States – Forecast For Hepatitis B Administered Doses (Million), 2020 – 2026
    Figure-36:        United States – Polio Vaccine Market (Million US$), 2015 – 2019
    Figure-37:        United States – Forecast For Polio Vaccine Market (Million US$), 2020 – 2026
    Figure-38:        United States – Polio Immunized Infants (Million), 2015 – 2019
    Figure-39:        United States – Forecast For Polio Immunized Infants (Million), 2020 – 2026
    Figure-40:        United States – Polio Administered Doses (Million), 2015 – 2019
    Figure-41:        United States – Forecast for Polio Administered Doses (Million), 2020 – 2026
    Figure-42:        United States – DTaP Vaccines Market (Million US$), 2015 – 2019
    Figure-43:        United States – Forecast For DTaP Vaccines Market (Million US$), 2020 – 2026
    Figure-44:        United States – DTaP Immunized Population (Million), 2015 – 2019
    Figure-45:        United States – Forecast For DTaP Immunized Population (Million), 2020 – 2026
    Figure-46:        United States – DTaP Administered Doses (Million), 2015 – 2019
    Figure-47:        United States – Forecast For DTaP Administered Doses (Million), 2020 – 2026
    Figure-48:        United States – HIB Vaccine Market (Million US$), 2015 – 2019
    Figure-49:        United States – Forecast For – HIB Vaccine Market (Million US$), 2020 – 2026
    Figure-50:        United States – HIB Immunized Infants (Million), 2015 – 2019
    Figure-51:        United States – Forecast For HIB Immunized Infants (Million ), 2020 – 2026
    Figure-52:        United States – HIB Administered Doses (Million), 2015 – 2019
    Figure-53:        United States – Forecast For HIB Administered Doses (Million), , 2020 – 2026
    Figure-54:        United States – Pneumococcal conjugate Vaccines Market (Million US$), 2015 – 2019
    Figure-55:        United States – Pneumococcal conjugate Vaccines Market (Million US$), 2020 – 2026
    Figure-56:        United States – Pneumococcal conjugate Immunized Population (Million), 2015 – 2019
    Figure-57:        United States – Forecast For Pneumococcal conjugate Immunized Population (Million), 2020 – 2026
    Figure-58:        United States – Pneumococcal conjugate Administered Doses (Million), 2015 – 2019
    Figure-59:        United States – Forecast For Pneumococcal conjugate Administered Doses (Million), 2020 – 2026
    Figure-60:        United States – Varicella Vaccines Market (Million US$), 2015 – 2019
    Figure-61:        United States – Forecast For Varicella Vaccines Market (Million US$), 2020 – 2026
    Figure-62:        United States – Varicella Immunized Infants (Million), 2015 – 2019
    Figure-63:        United States – Forecast For Varicella Immunized Infants (Million), 2020 – 2026
    Figure-64:        United States – Varicella Administered Doses (Million), 2015 – 2019
    Figure-65:        United States – Forecast For Varicella Administered Doses (Million), 2020 – 2026
    Figure-66:        United States – MMR Vaccine Market (Million US$), 2015 – 2019
    Figure-67:        United States – Forecast For MMR Vaccine Market (Million US$), 2020 – 2026
    Figure-68:        United States – MMR Immunized Population (Million), 2015 – 2019
    Figure-69:        United States – Forecast For MMR Immunized Population (Million ), 2020 – 2026
    Figure-70:        United States – Administered Doses (Million), 2015 – 2019
    Figure-71:        United States – Forecast For Administered Doses (Million), 2020 – 2026
    Figure-72:        United States – HPV Vaccine Market (Million US$), 2015 – 2019
    Figure-73:        United States – Forecast For HPV Vaccine Market (Million), 2020 – 2026
    Figure-74:        United States – HPV Immunized Girl (Million), 2015 – 2019
    Figure-75:        United States – Forecast For HPV Immunized Girl (Million), 2020 – 2026
    Figure-76:        United States – HPV Administered Doses (Million), 2015 – 2019
    Figure-77:        United States – Forecast For HPV Administered Doses (Million ), 2020 – 2026
    Figure-78:        Global – GlaxoSmithKline, plc.'s Vaccine Revenue (Million US$), 2015 – 2019
    Figure-79:        Global – Forecast For GlaxoSmithKline plc.'s Vaccine Revenue (Million US$), 2020 – 2026
    Figure-80:        Global – Merck & Co. Vaccine Revenue (Million US$), 2015 – 2019
    Figure-81:        Global – Forecast For Merck & Co. Vaccine Revenue (Million US$), 2020 – 2026
    Figure-82:        Global – Sanofi Pasteur’s Vaccines Revenue (Million US$), 2015 – 2019
    Figure-83:        Global – Forecast For Sanofi Pasteur’s Vaccines Revenue ( Million US$) 2020 – 2026
    Figure-84:        Global – Pfizer, Inc.’s Vaccine Revenue (Million US$), 2015 – 2020
    Figure-85:        Global – Forecast For Pfizer, Inc.’s Vaccine Revenue (Million US$), 2020 – 2026

     

    List of Tables:

    Table-01:        United States – Market Share by Vaccine Type (Percentage), 2017 – 2020
    Table-02:        United States – Forecast For Market Share by Vaccine Type (Percentage), 2020 – 2026
    Table-03:        United States – Volume Share by Vaccine Type (Percentage), 2017 – 2020
    Table-04:        United States – Forecast For Volume Share by Vaccine Type (Percentage), 2020 – 2026
    Table-05:        GlaxoSmithKline, plc. Products & Pipelines
    Table-06:        Sanofi Pasteur Products & Pipelines
    Table-07:        Pfizer Products & Pipelines

    Related Reports

    About Renub

    Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting.

    Connect with us

    +1-478-202-3244

    IN +91-120-421-9822

    info@renub.com

    Useful Links

    Latest News